IntelGenx Technologies (IGXT) has released an update.
IntelGenx Technologies Corp. has reported an increase in revenue to $1.04 million for 2023, up from $950,000 the previous year, alongside a reduction in net comprehensive loss from $11.6 million to $10.1 million. The company anticipates a significant revenue boost in 2024 with the Q2 launch of its RIZAFILM product in the United States by Gensco Pharma. Additionally, the company has secured funding through private placements and a Regulation A offering, while also progressing in pharmaceutical and veterinary product development.
For further insights into IGXT stock, check out TipRanks’ Stock Analysis page.
